Skip to content
Advertisement

Articles by Tom Howell Jr.

A person is injected with her second dose of the Pfizer COVID-19 vaccine at a Dallas County Health and Human Services vaccination site in Dallas, Thursday, Aug. 26, 2021.  Federal health regulators on Friday, Feb. 11, 2022 delayed next week's public meeting to review Pfizers COVID-19 vaccine for children under 5, saying they want to see more data. (AP Photo/LM Otero, File)

FDA postpones review of child COVID-19 vaccine

The Food and Drug Administration on Friday postponed an advisory meeting on Pfizer-BioNTech's vaccine for young children and will wait for data on the third dose from trials, meaning the rollout for ages 0 to 4 might not begin until April.

February 11, 2022